Chemomab Therapeutics Reveals Receipt Of Nasdaq Notice Regarding Minimum Bid Price Requirement
Portfolio Pulse from Benzinga Newsdesk
Chemomab Therapeutics has received a notice from Nasdaq regarding the minimum bid price requirement. The company's stock has been trading below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market.
November 06, 2023 | 9:17 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Chemomab Therapeutics has been notified by Nasdaq about its failure to meet the minimum bid price requirement. This could potentially lead to the company's delisting from the Nasdaq Capital Market.
The receipt of a notice from Nasdaq regarding the minimum bid price requirement is a serious issue. If Chemomab Therapeutics fails to raise its stock price above $1.00 per share, it risks being delisted from the Nasdaq Capital Market. This could negatively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100